Manages symptom complex of tension (or muscle contraction) headache. ANDA 215138, held by Hikma. Acetaminophen; Butalbital; Caffeine; Codeine Phosphate.
As of Nov 16, 2026, ANDA 215138 (Butalbital, Acetaminophen, Caffeine And Codeine Phosphate), held by Hikma, was first approved by FDA on Jan 26, 2022, with 2 approved supplements and 0 published complete response letters.
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2022 | Original application | Approved |
| Butalbital, Acetaminophen, Caffeine And Codeine Phosphate325MG;50MG;40MG;30MG · capsule;oral | Acetaminophen; Butalbital; Caffeine; Codeine Phosphate | Rx |
| Butalbital, Acetaminophen, Caffeine And Codeine Phosphate300MG;50MG;40MG;30MG · capsule;oral | Acetaminophen; Butalbital; Caffeine; Codeine Phosphate | Rx |
| Jun 18, 2026 | Supplement 7REMS | Approved | None posted |
| Oct 31, 2024 | Supplement 2REMS | Approved | None posted |
| Jan 26, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters